|
US7179892B2
(en)
*
|
2000-12-06 |
2007-02-20 |
Neuralab Limited |
Humanized antibodies that recognize beta amyloid peptide
|
|
US6787523B1
(en)
|
1997-12-02 |
2004-09-07 |
Neuralab Limited |
Prevention and treatment of amyloidogenic disease
|
|
US7964192B1
(en)
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
|
US20080050367A1
(en)
*
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
|
US7790856B2
(en)
|
1998-04-07 |
2010-09-07 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize beta amyloid peptide
|
|
US7588766B1
(en)
|
2000-05-26 |
2009-09-15 |
Elan Pharma International Limited |
Treatment of amyloidogenic disease
|
|
TWI239847B
(en)
*
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
|
US6905686B1
(en)
|
1997-12-02 |
2005-06-14 |
Neuralab Limited |
Active immunization for treatment of alzheimer's disease
|
|
US6761888B1
(en)
|
2000-05-26 |
2004-07-13 |
Neuralab Limited |
Passive immunization treatment of Alzheimer's disease
|
|
US6750324B1
(en)
|
1997-12-02 |
2004-06-15 |
Neuralab Limited |
Humanized and chimeric N-terminal amyloid beta-antibodies
|
|
US6913745B1
(en)
|
1997-12-02 |
2005-07-05 |
Neuralab Limited |
Passive immunization of Alzheimer's disease
|
|
US6923964B1
(en)
|
1997-12-02 |
2005-08-02 |
Neuralab Limited |
Active immunization of AScr for prion disorders
|
|
US20050059802A1
(en)
*
|
1998-04-07 |
2005-03-17 |
Neuralab Ltd |
Prevention and treatment of amyloidogenic disease
|
|
US20030147882A1
(en)
|
1998-05-21 |
2003-08-07 |
Alan Solomon |
Methods for amyloid removal using anti-amyloid antibodies
|
|
US6787637B1
(en)
|
1999-05-28 |
2004-09-07 |
Neuralab Limited |
N-Terminal amyloid-β antibodies
|
|
UA81216C2
(en)
|
1999-06-01 |
2007-12-25 |
|
Prevention and treatment of amyloid disease
|
|
ATE405636T1
(de)
|
1999-06-16 |
2008-09-15 |
Boston Biomedical Res Inst |
Immunologische kontrolle des beta-amyloid gehaltes in vivo
|
|
SK288711B6
(sk)
|
2000-02-24 |
2019-11-05 |
Univ Washington |
Humanizovaná protilátka, jej fragment a ich použitie, polynukleová kyselina, expresný vektor, bunka a farmaceutický prostriedok
|
|
US7700751B2
(en)
|
2000-12-06 |
2010-04-20 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize β-amyloid peptide
|
|
PE20020574A1
(es)
|
2000-12-06 |
2002-07-02 |
Wyeth Corp |
Anticuerpos humanizados que reconocen el peptido amiloideo beta
|
|
EP1385545B1
(en)
*
|
2001-04-30 |
2009-01-07 |
Eli Lilly And Company |
Humanized antibodies recognizing the beta-amyloid peptide
|
|
EP1385544B1
(en)
*
|
2001-04-30 |
2008-09-24 |
Eli Lilly And Company |
Humanized antibodies
|
|
US20020197258A1
(en)
*
|
2001-06-22 |
2002-12-26 |
Ghanbari Hossein A. |
Compositions and methods for preventing protein aggregation in neurodegenerative diseases
|
|
WO2003014162A1
(en)
†
|
2001-08-03 |
2003-02-20 |
Medical & Biological Laboratories Co., Ltd. |
ANTIBODY RECOGNIZING GM1 GANGLIOSIDE-BOUND AMYLOID β-PROTEIN AND DNA ENCODING THE ANTIBODY
|
|
EP1432444A4
(en)
*
|
2001-08-17 |
2005-11-02 |
Lilly Co Eli |
ANTI-BETA ANTIBODIES
|
|
JP2005500389A
(ja)
*
|
2001-08-17 |
2005-01-06 |
イーライ・リリー・アンド・カンパニー |
Ａβに関連する病態および疾患を治療するための、可溶性Ａβに高い親和性を有する抗体の使用
|
|
AU2002324468A1
(en)
*
|
2001-08-17 |
2003-03-03 |
Eli Lilly And Company |
Rapid improvement of cognition in conditions related to abeta
|
|
PT1416965E
(pt)
*
|
2001-08-17 |
2008-04-01 |
Lilly Co Eli |
Método de ensaio para a doença de alzheimer
|
|
PT1944040E
(pt)
|
2001-08-17 |
2012-10-31 |
Univ Washington |
Método de avaliação para a doença de alzheimer
|
|
US7179606B2
(en)
*
|
2001-11-23 |
2007-02-20 |
Syn X Pharma, Inc. |
IG heavy chain, IG kappa, IG lambda biopolymer markers predictive of Alzheimer's disease
|
|
MY139983A
(en)
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
|
ATE419871T1
(de)
*
|
2002-04-25 |
2009-01-15 |
Lilly Co Eli |
Verfahren zur behandlung von angststörungen bei älteren personen
|
|
WO2004029629A1
(en)
*
|
2002-09-27 |
2004-04-08 |
Janssen Pharmaceutica N.V. |
N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses
|
|
FR2846667B1
(fr)
*
|
2002-11-06 |
2004-12-31 |
Pasteur Institut |
Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives
|
|
WO2004056318A2
(en)
|
2002-12-19 |
2004-07-08 |
New York University |
Method for treating amyloid disease
|
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
|
EP1594969B1
(en)
*
|
2003-02-01 |
2015-05-20 |
Janssen Sciences Ireland UC |
Active immunization to generate antibodies to soluble a-beta
|
|
US7575747B2
(en)
|
2003-02-10 |
2009-08-18 |
Applied Molecular Evolution |
Aβ binding molecules
|
|
US8663650B2
(en)
|
2003-02-21 |
2014-03-04 |
Ac Immune Sa |
Methods and compositions comprising supramolecular constructs
|
|
US7732162B2
(en)
|
2003-05-05 |
2010-06-08 |
Probiodrug Ag |
Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
|
|
TWI306458B
(en)
*
|
2003-05-30 |
2009-02-21 |
Elan Pharma Int Ltd |
Humanized antibodies that recognize beta amyloid peptide
|
|
US7736644B2
(en)
|
2003-06-27 |
2010-06-15 |
Amgen Fremont Inc. |
Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
|
|
KR101139103B1
(ko)
*
|
2003-09-12 |
2012-07-05 |
아피리스 아게 |
아페레시스 장치
|
|
AT413336B
(de)
*
|
2003-09-12 |
2006-02-15 |
Mattner Frank Dr |
Apherese-vorrichtung
|
|
US7848543B2
(en)
*
|
2004-02-05 |
2010-12-07 |
Brainlab Ag |
Method and system for prediction and management of material and information transport in an organism
|
|
US20070190046A1
(en)
*
|
2004-02-23 |
2007-08-16 |
Eli Lilly And Company |
Anti-abeta antibody
|
|
WO2005105998A1
(ja)
*
|
2004-04-27 |
2005-11-10 |
Juridical Foundation The Chemo-Sero-Therapeutic Research Institute |
ヒト抗アミロイドβペプチド抗体およびその抗体フラグメント
|
|
EP1769002A1
(en)
*
|
2004-07-02 |
2007-04-04 |
Northwestern University |
Monolocal antibodies that target pathological assemblies of amyloid beta; (abeta)
|
|
US20060024667A1
(en)
|
2004-07-29 |
2006-02-02 |
Karen Manucharyan |
Compositions and methods for Alzheimer's disease
|
|
JP2008515438A
(ja)
*
|
2004-10-05 |
2008-05-15 |
ワイス |
組換えタンパク質産生の改善方法および組成物
|
|
US9901413B2
(en)
*
|
2004-10-15 |
2018-02-27 |
Brainlab Ag |
Targeted infusion of agents for treatment of ALS
|
|
US9924888B2
(en)
*
|
2004-10-15 |
2018-03-27 |
Brainlab Ag |
Targeted infusion of agents against parkinson's disease
|
|
US9907485B2
(en)
*
|
2004-10-15 |
2018-03-06 |
Brainlab Ag |
Targeted immunization and plaque destruction against Alzheimer's disease
|
|
CA2589017A1
(en)
*
|
2004-12-15 |
2006-06-22 |
Neuralab Limited |
Amyloid beta antibodies for use in improving cognition
|
|
AR052051A1
(es)
|
2004-12-15 |
2007-02-28 |
Neuralab Ltd |
Anticuerpos ab humanizados usados en mejorar la cognicion
|
|
WO2006066049A2
(en)
*
|
2004-12-15 |
2006-06-22 |
Neuralab Limited |
Humanized antibodies that recognize beta amyloid peptide
|
|
EP1827493A4
(en)
*
|
2004-12-22 |
2009-09-30 |
Univ St Louis |
USE OF ANTI-ABETA ANTIBODIES FOR THE TREATMENT OF BRAIN TRAUMA
|
|
WO2006081171A1
(en)
*
|
2005-01-24 |
2006-08-03 |
Amgen Inc. |
Humanized anti-amyloid antibody
|
|
GT200600031A
(es)
|
2005-01-28 |
2006-08-29 |
|
Formulacion anticuerpo anti a beta
|
|
EP1896504B1
(en)
|
2005-06-17 |
2012-11-21 |
Wyeth LLC |
Methods of purifying fc region containing antibodies
|
|
PT2289909E
(pt)
|
2005-11-30 |
2015-02-10 |
Abbvie Inc |
Método de rastreio, processo de purificação de globulómeros a-beta não difundíveis, anticorpos selectivos contra os referidos globulómeros a-beta não difundíveis e processo para o fabrico dos referidos anticorpos
|
|
PL1976877T5
(pl)
*
|
2005-11-30 |
2017-09-29 |
Abbvie Inc |
Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
|
|
EP2808032B1
(en)
|
2005-12-12 |
2018-08-01 |
AC Immune S.A. |
A beta 1-42 specific monoclonal antibodies with therapeutic properties
|
|
DOP2006000278A
(es)
|
2005-12-12 |
2007-07-15 |
Hoffmann La Roche |
Glicosilación en la región variable
|
|
KR20120093400A
(ko)
*
|
2006-03-30 |
2012-08-22 |
글락소 그룹 리미티드 |
아밀로이드?베타 펩티드에 대한 항체
|
|
US8784810B2
(en)
|
2006-04-18 |
2014-07-22 |
Janssen Alzheimer Immunotherapy |
Treatment of amyloidogenic diseases
|
|
CN101058608B
(zh)
*
|
2006-04-21 |
2011-02-23 |
杜如昱 |
人类抗Aβ1-32淀粉样蛋白抗体、其纯化方法及用途
|
|
EP3988566A1
(en)
*
|
2006-07-14 |
2022-04-27 |
AC Immune SA |
Humanized antibody against amyloid beta
|
|
CL2007002070A1
(es)
|
2006-07-14 |
2008-02-08 |
Ac Immune S A Genentech Inc |
Anticuerpo quimerico o humanizado, o fragmentos de ellos, que se adhieren especificamente a por lo menos un epitopo en la proteina beta-amiloide; molecula de acido nucleico que lo codifica; composicion que lo comprende; su uso para tratar enfermedade
|
|
KR20160049045A
(ko)
*
|
2006-07-14 |
2016-05-04 |
에이씨 이뮨 에스.에이. |
아밀로이드 베타에 대해 인간화된 항체
|
|
NO348280B1
(no)
*
|
2006-07-14 |
2024-11-04 |
Genentech Inc |
Humanisert antistoff
|
|
ES2640095T3
(es)
*
|
2006-10-02 |
2017-10-31 |
Ac Immune S.A. |
Anticuerpo humanizado contra beta-amiloide
|
|
AU2007308145A1
(en)
|
2006-10-12 |
2008-04-17 |
Wyeth |
Modification of ionic strength in antibody-solutions to reduce opalescence/aggregates
|
|
US8455626B2
(en)
*
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
|
SI2104682T1
(sl)
|
2007-01-11 |
2017-05-31 |
Michael Bacher |
Diagnostika in zdravljenje Alzheimerjeve bolezni in drugih nevrodementnih bolezni
|
|
ES2615454T3
(es)
|
2007-01-18 |
2017-06-07 |
Eli Lilly And Company |
Fab pegilado contra el amiloide beta
|
|
AU2008215948A1
(en)
|
2007-02-12 |
2008-08-21 |
Merck & Co., Inc. |
Piperazine derivatives for treatment of AD and related conditions
|
|
WO2008104386A2
(en)
|
2007-02-27 |
2008-09-04 |
Abbott Gmbh & Co. Kg |
Method for the treatment of amyloidoses
|
|
EA200901140A1
(ru)
|
2007-03-01 |
2010-04-30 |
Пробиодруг Аг |
Новое применение ингибиторов глутаминилциклазы
|
|
EP2142514B1
(en)
|
2007-04-18 |
2014-12-24 |
Probiodrug AG |
Thiourea derivatives as glutaminyl cyclase inhibitors
|
|
US8003097B2
(en)
|
2007-04-18 |
2011-08-23 |
Janssen Alzheimer Immunotherapy |
Treatment of cerebral amyloid angiopathy
|
|
JP2011526240A
(ja)
*
|
2007-04-18 |
2011-10-06 |
ヤンセン アルツハイマー イミュノセラピー |
脳アミロイド血管症の予防および治療
|
|
WO2008144232A2
(en)
|
2007-05-18 |
2008-11-27 |
The Johns Hopkins University |
A treatment simulator for brain diseases and method of use thereof
|
|
US20090232801A1
(en)
*
|
2007-05-30 |
2009-09-17 |
Abbot Laboratories |
Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
|
|
JP2010528583A
(ja)
*
|
2007-06-11 |
2010-08-26 |
エーシー イミューン ソシエテ アノニム |
アミロイドβに対するヒト化抗体
|
|
CN101820911B
(zh)
*
|
2007-06-12 |
2015-05-06 |
Ac免疫有限公司 |
β淀粉样蛋白的人源化抗体
|
|
US8613923B2
(en)
|
2007-06-12 |
2013-12-24 |
Ac Immune S.A. |
Monoclonal antibody
|
|
SI2182983T1
(sl)
|
2007-07-27 |
2014-09-30 |
Janssen Alzheimer Immunotherapy |
Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta
|
|
CN101842388B
(zh)
*
|
2007-09-13 |
2013-09-04 |
德勒尼克斯治疗股份公司 |
针对β淀粉样肽的人源化抗体
|
|
WO2009048537A2
(en)
*
|
2007-10-05 |
2009-04-16 |
Genentech, Inc. |
Humanized antibody
|
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
|
DK2207568T3
(en)
*
|
2007-11-16 |
2017-09-18 |
Univ Rockefeller |
ANTIBODIES SPECIFIC TO THE PROTOFIBRILE FORM OF BETA AMYLOID PROTEIN
|
|
EP2261254A3
(en)
|
2007-12-21 |
2011-04-13 |
Amgen, Inc |
Anti-amyloid antibodies and uses thereof
|
|
EP2106802A1
(en)
|
2008-04-02 |
2009-10-07 |
SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. |
Modified peptides as synthetic vaccines in amyloid-associated disease
|
|
EP2149380A1
(en)
*
|
2008-07-29 |
2010-02-03 |
Medivet Pharma, S.L. |
Veterinary immunotherapy compositions for the Aged Related Cognitive Dysfunction.
|
|
US8815794B2
(en)
|
2008-08-28 |
2014-08-26 |
The Research Foundation For The State University Of New York |
Treatment of amyloidoses using myelin basic protein and fragments thereof
|
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
|
US8614297B2
(en)
|
2008-12-22 |
2013-12-24 |
Hoffmann-La Roche Inc. |
Anti-idiotype antibody against an antibody against the amyloid β peptide
|
|
CN102695546B
(zh)
|
2009-09-11 |
2014-09-10 |
前体生物药物股份公司 |
作为谷氨酰胺酰环化酶抑制剂的杂环衍生物
|
|
BR112012014060B8
(pt)
|
2009-12-11 |
2021-07-27 |
Araclon Biotech Sl |
método para o diagnóstico da doença de alzheimer em um sujeito, para detecção da disfunção cognitiva branda ou para diferenciar a doença de alzheimer da disfunção cognitiva branda
|
|
WO2011109246A1
(en)
|
2010-03-01 |
2011-09-09 |
The J. David Gladstone Institutes |
Antibody specific for apolipoprotein and methods of use thereof
|
|
WO2011107530A2
(en)
|
2010-03-03 |
2011-09-09 |
Probiodrug Ag |
Novel inhibitors
|
|
SG183229A1
(en)
|
2010-03-10 |
2012-09-27 |
Probiodrug Ag |
Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
|
|
CA2796339C
(en)
|
2010-04-15 |
2020-03-31 |
Abbott Laboratories |
Amyloid-beta binding proteins
|
|
EP2560953B1
(en)
|
2010-04-21 |
2016-01-06 |
Probiodrug AG |
Inhibitors of glutaminyl cyclase
|
|
WO2011149461A1
(en)
|
2010-05-27 |
2011-12-01 |
Medtronic, Inc. |
Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
|
|
CA2807552A1
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
MX358739B
(es)
|
2010-08-14 |
2018-09-03 |
Abbvie Inc Star |
Proteinas de union a amiloide beta.
|
|
SI3590949T1
(sl)
|
2010-10-01 |
2022-09-30 |
Modernatx, Inc. |
Ribonukleinske kisline, ki vsebujejo N1-metil-psevdouracil, in njihove uporabe
|
|
WO2012123563A1
(en)
|
2011-03-16 |
2012-09-20 |
Probiodrug Ag |
Benz imidazole derivatives as inhibitors of glutaminyl cyclase
|
|
JP2014511687A
(ja)
|
2011-03-31 |
2014-05-19 |
モデルナ セラピューティクス インコーポレイテッド |
工学操作された核酸の送達および製剤
|
|
WO2012131539A1
(en)
|
2011-03-31 |
2012-10-04 |
Pfizer Inc. |
Novel bicyclic pyridinones
|
|
EP2511296A1
(en)
|
2011-04-12 |
2012-10-17 |
Araclón Biotech, S. L. |
Antibody, kit and method for determination of amyloid peptides
|
|
WO2012172449A1
(en)
|
2011-06-13 |
2012-12-20 |
Pfizer Inc. |
Lactams as beta secretase inhibitors
|
|
WO2013030713A1
(en)
|
2011-08-31 |
2013-03-07 |
Pfizer Inc. |
Hexahydropyrano [3,4-d][1,3] thiazin-2-amine compounds
|
|
JP2012050437A
(ja)
*
|
2011-09-12 |
2012-03-15 |
Janssen Alzheimer Immunotherapy |
ベータアミロイドペプチドを認識するヒト化抗体
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
EP2763701B1
(en)
|
2011-10-03 |
2018-12-19 |
Moderna Therapeutics, Inc. |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
|
RU2649364C2
(ru)
|
2011-12-16 |
2018-04-02 |
Модерна Терапьютикс, Инк. |
Составы на основе модифицированного нуклеозида, нуклеотида и нуклеиновой кислоты
|
|
US9963511B2
(en)
*
|
2011-12-22 |
2018-05-08 |
Hoffmann-La Roche Inc. |
Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides
|
|
EP3520821A1
(en)
|
2012-04-02 |
2019-08-07 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of biologics and proteins associated with human disease
|
|
US9878056B2
(en)
|
2012-04-02 |
2018-01-30 |
Modernatx, Inc. |
Modified polynucleotides for the production of cosmetic proteins and peptides
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
CA2872154C
(en)
|
2012-05-04 |
2016-08-23 |
Pfizer Inc. |
Heterocyclic substituted hexahydropyrano [3,4-d] [1,3] thiazin-2-amine compounds as inhibitors of app, bace1 and bace2
|
|
MD20140130A2
(ro)
|
2012-06-29 |
2015-04-30 |
Pfizer Inc. |
4-(amino-substituite)-7H-pirolo[2,3-d]pirimidine noi ca inhibitori de LRRK2
|
|
BR112014033066A2
(pt)
*
|
2012-07-03 |
2017-08-01 |
Janssen Alzheimer Immunotherap |
método para tratamento de um paciente diagnosticado com doença de alzheimer, forma humanizada, quimérica ou revestida de um anticorpo, e, anticorpo.
|
|
WO2014045162A1
(en)
|
2012-09-20 |
2014-03-27 |
Pfizer Inc. |
ALKYL-SUBSTITUTED HEXAHYDROPYRANO[3,4-d] [1,3]THIAZIN-2-ANIME COMPOUNDS
|
|
UA110688C2
(uk)
|
2012-09-21 |
2016-01-25 |
Пфайзер Інк. |
Біциклічні піридинони
|
|
SI2922554T1
(sl)
|
2012-11-26 |
2022-06-30 |
Modernatx, Inc. |
Terminalno modificirana RNA
|
|
EP2931731A1
(en)
|
2012-12-11 |
2015-10-21 |
Pfizer Inc. |
Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1
|
|
JP6162820B2
(ja)
|
2012-12-19 |
2017-07-12 |
ファイザー・インク |
炭素環式および複素環式置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
|
|
WO2014125394A1
(en)
|
2013-02-13 |
2014-08-21 |
Pfizer Inc. |
HETEROARYL-SUBSTITUTED HEXAHYDROPYRANO [3,4-d][1,3] THIAZIN-2-AMINE COMPOUNDS
|
|
US9233981B1
(en)
|
2013-02-15 |
2016-01-12 |
Pfizer Inc. |
Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
|
|
EA201591360A1
(ru)
|
2013-02-19 |
2016-03-31 |
Пфайзер Инк. |
Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
AR096364A1
(es)
|
2013-05-20 |
2015-12-23 |
Genentech Inc |
Anticuerpos receptores de antitransferina y métodos de uso
|
|
MX2016002799A
(es)
|
2013-09-13 |
2016-05-26 |
Genentech Inc |
Composiciones y metodos para detectar y cuantificar la proteina en la celula hospedera en las lineas de celulas y productos de polipeptidos recombinantes.
|
|
WO2015038888A1
(en)
|
2013-09-13 |
2015-03-19 |
Genentech, Inc. |
Methods and compositions comprising purified recombinant polypeptides
|
|
US10023626B2
(en)
|
2013-09-30 |
2018-07-17 |
Modernatx, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
KR20160067219A
(ko)
|
2013-10-03 |
2016-06-13 |
모더나 세라퓨틱스, 인코포레이티드 |
저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
|
|
JP6425717B2
(ja)
|
2013-10-04 |
2018-11-21 |
ファイザー・インク |
ガンマセクレターゼモジュレーターとしての新規二環式ピリジノン
|
|
WO2015092592A1
(en)
|
2013-12-17 |
2015-06-25 |
Pfizer Inc. |
Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
|
|
CR20160454A
(es)
|
2014-04-01 |
2016-12-06 |
Pfizer |
CROMENO Y 1,1 a,2,7b—TETRAHIDROCICLOPROPA[C]CROMENO PIRIDOPIRAZINADIONAS NOVEDOSAS
|
|
AU2015245260A1
(en)
|
2014-04-10 |
2016-10-06 |
Pfizer Inc. |
2-amino-6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,3-thiazol-4-yl amides
|
|
WO2015165961A1
(en)
|
2014-04-29 |
2015-11-05 |
Affiris Ag |
Treatment and prevention of alzheimer's disease (ad)
|
|
EP3172210B1
(en)
|
2014-07-24 |
2020-01-15 |
Pfizer Inc |
Pyrazolopyrimidine compounds
|
|
AU2015298378B2
(en)
|
2014-08-06 |
2018-08-02 |
Pfizer Inc. |
Imidazopyridazine compounds
|
|
WO2016081643A1
(en)
|
2014-11-19 |
2016-05-26 |
Genentech, Inc. |
Anti-transferrin receptor antibodies and methods of use
|
|
EP3221361B1
(en)
|
2014-11-19 |
2021-04-21 |
Genentech, Inc. |
Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
|
|
HRP20210124T1
(hr)
|
2014-11-19 |
2021-03-19 |
Axon Neuroscience Se |
Humanizirana tau antitijela u alzheimerovoj bolesti
|
|
DK3253755T3
(da)
|
2015-02-03 |
2020-09-28 |
Pfizer |
Hidtil ukendte cyclopropabenzofuranyl-pyridopyrazindioner
|
|
TN2017000485A1
(en)
|
2015-06-17 |
2019-04-12 |
Pfizer |
Tricyclic compounds and their use as phosphodiesterase inhibitors
|
|
CA2991856A1
(en)
*
|
2015-07-21 |
2017-01-26 |
Bioarctic Neuroscience Ab |
Method for treatment of traumatic brain injury targeting aggregated peptides
|
|
RU2722149C1
(ru)
|
2015-09-14 |
2020-05-27 |
Пфайзер Инк. |
Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2
|
|
AU2016325665A1
(en)
|
2015-09-24 |
2018-03-08 |
Pfizer Inc. |
N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3] thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl] amides
|
|
JP2018531924A
(ja)
|
2015-09-24 |
2018-11-01 |
ファイザー・インク |
テトラヒドロピラノ［３，４−ｄ］［１，３］オキサジン誘導体、およびｂａｃｅ阻害剤としてのその使用
|
|
EP3353174A1
(en)
|
2015-09-24 |
2018-08-01 |
Pfizer Inc |
N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl]amides useful as bace inhibitors
|
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
|
CN116196410A
(zh)
|
2015-10-28 |
2023-06-02 |
宾夕法尼亚州大学信托人 |
鞘内施用腺伴随病毒载体用于基因治疗
|
|
CN108350052A
(zh)
*
|
2015-11-09 |
2018-07-31 |
英属哥伦比亚大学 |
淀粉样蛋白β中间区域中的表位及其构象选择性抗体
|
|
EP3374379A4
(en)
|
2015-11-09 |
2019-05-15 |
The University Of British Columbia |
N-TERMINAL EPITOPES IN AMYLOID BETA AND CONFORMATION-SELECTIVE ANTIBODIES
|
|
JP7452829B2
(ja)
|
2015-11-09 |
2024-03-19 |
ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア |
アミロイドベータのエピトープおよびそれに対する抗体
|
|
CN108699080B
(zh)
|
2016-02-23 |
2021-05-14 |
辉瑞公司 |
6,7-二氢-5H-吡唑并[5,1-b][1,3]噁嗪-2-甲酰胺化合物
|
|
SG11201811712QA
(en)
|
2016-07-01 |
2019-01-30 |
Pfizer |
5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases
|
|
TWI798751B
(zh)
|
2016-07-01 |
2023-04-11 |
美商美國禮來大藥廠 |
抗－N3pGlu類澱粉β肽抗體及其用途
|
|
WO2018014126A1
(en)
|
2016-07-18 |
2018-01-25 |
The University Of British Columbia |
Antibodies to amyloid beta
|
|
EP3496750A2
(en)
*
|
2016-08-09 |
2019-06-19 |
Eli Lilly and Company |
Combination therapy
|
|
US20200055917A1
(en)
|
2016-09-27 |
2020-02-20 |
Cero Therapeutics, Inc. |
Chimeric engulfment receptor molecules
|
|
CA3042236A1
(en)
*
|
2016-10-28 |
2018-05-03 |
Washington University |
Anti-apoe antibodies
|
|
US20180125920A1
(en)
|
2016-11-09 |
2018-05-10 |
The University Of British Columbia |
Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
|
|
EP3592740B1
(en)
|
2017-03-10 |
2022-02-09 |
Pfizer Inc. |
Cyclic substituted imidazo[4,5-c]quinoline derivatives
|
|
EP3592741B1
(en)
|
2017-03-10 |
2023-02-15 |
Pfizer Inc. |
Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors
|
|
JOP20190247A1
(ar)
*
|
2017-04-20 |
2019-10-20 |
Lilly Co Eli |
أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها
|
|
US20230137562A1
(en)
|
2017-06-07 |
2023-05-04 |
Adrx, Inc. |
Tau aggregation inhibitors
|
|
FI3642202T3
(fi)
|
2017-06-22 |
2023-03-01 |
|
Dihydro-pyrrolo-pyridiinijohdannaisia
|
|
AU2018290898B2
(en)
*
|
2017-06-29 |
2021-03-11 |
The Trustees Of Columbia University In The City Of New York |
Chimeric antibodies for treatment of amyloid deposition diseases
|
|
CA3070085A1
(en)
|
2017-07-18 |
2019-01-24 |
Promis Neurosciences Inc. |
Antibodies to amyloid beta
|
|
US12286469B2
(en)
|
2017-07-18 |
2025-04-29 |
The University Of British Columbia |
Humanized antibodies binding to amyloid-beta (A-beta)
|
|
US12227567B2
(en)
|
2017-07-25 |
2025-02-18 |
Truebinding, Inc. |
Treating cancer by blocking the interaction of TIM-3 and its ligand
|
|
US11382974B2
(en)
|
2017-08-01 |
2022-07-12 |
The Trustees Of Columbia University In The City Of New York |
Methods and compositions for treatment of amyloid deposition diseases
|
|
US11453701B2
(en)
|
2017-08-18 |
2022-09-27 |
Adrx, Inc. |
Tau aggregation peptide inhibitors
|
|
WO2019067328A1
(en)
|
2017-09-26 |
2019-04-04 |
Cero Therapeutics, Inc. |
CHIMERIC ENGINEERING RECEPTOR MOLECULES AND METHODS OF USE
|
|
DK3461819T3
(da)
|
2017-09-29 |
2020-08-10 |
Probiodrug Ag |
Inhibitorer af glutaminylcyklase
|
|
WO2019074840A1
(en)
*
|
2017-10-09 |
2019-04-18 |
Keith Black |
COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE AND OTHER AMYLOID RELATED DISEASES
|
|
WO2019183636A1
(en)
|
2018-03-23 |
2019-09-26 |
Pfizer Inc. |
Piperazine azaspiro derivaves
|
|
JP7444781B2
(ja)
|
2018-03-28 |
2024-03-06 |
セロ・セラピューティクス・インコーポレイテッド |
細胞免疫療法組成物およびその使用
|
|
WO2019191332A1
(en)
|
2018-03-28 |
2019-10-03 |
Cero Therapeutics, Inc. |
Chimeric engulfment receptors and uses thereof for neurodegenerative diseases
|
|
US20210309726A1
(en)
*
|
2018-05-21 |
2021-10-07 |
New York University |
Treatment of melanoma brain metastasis by inhibition of amyloid precursor protein cleavage
|
|
US12018069B2
(en)
|
2018-06-28 |
2024-06-25 |
The Trustees Of Columbia University In The City Of New York |
Methods and compositions for imaging amyloid deposits
|
|
CA3115071A1
(en)
|
2018-10-04 |
2020-04-09 |
University Of Rochester |
Improvement of glymphatic delivery by manipulating plasma osmolarity
|
|
WO2020132230A2
(en)
|
2018-12-20 |
2020-06-25 |
Genentech, Inc. |
Modified antibody fcs and methods of use
|
|
FR3091999A1
(fr)
*
|
2019-01-25 |
2020-07-31 |
Mexbrain |
Dispositif d’extraction conjointe d’un cation métallique et d’une molécule cible
|
|
WO2021076620A1
(en)
|
2019-10-15 |
2021-04-22 |
Eli Lilly And Company |
Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
|
|
CA3185040A1
(en)
|
2020-05-26 |
2021-12-02 |
Truebinding, Inc. |
Methods of treating inflammatory diseases by blocking galectin-3
|
|
BR112023001061A2
(pt)
|
2020-07-23 |
2023-04-04 |
Othair Prothena Ltd |
Anticorpos antiabeta
|
|
TWI843040B
(zh)
|
2021-01-11 |
2024-05-21 |
美商美國禮來大藥廠 |
抗N3pGlu類澱粉β抗體及其用途
|
|
WO2022182658A1
(en)
|
2021-02-23 |
2022-09-01 |
Hoth Therapeutics, Inc. |
Use of aprepitant for treating alzheimer's disease
|
|
TW202300518A
(zh)
|
2021-03-12 |
2023-01-01 |
美商美國禮來大藥廠 |
抗N3pGlu類澱粉β抗體及其用途
|
|
TW202300517A
(zh)
|
2021-03-12 |
2023-01-01 |
美商美國禮來大藥廠 |
抗類澱粉β抗體及其用途
|
|
WO2022251048A1
(en)
|
2021-05-24 |
2022-12-01 |
Eli Lilly And Company |
Anti-amyloid beta antibodies and uses thereof
|
|
WO2023150483A1
(en)
|
2022-02-03 |
2023-08-10 |
Eli Lilly And Company |
Regional tau imaging for diagnosing and treating alzheimer's disease
|
|
WO2025032070A1
(en)
|
2023-08-09 |
2025-02-13 |
F. Hoffmann-La Roche Ag |
Anti-a-beta protein antibodies, methods and uses thereof
|
|
WO2025145091A1
(en)
|
2023-12-29 |
2025-07-03 |
Pfizer Inc. |
Crystalline forms of a muscarinic m4 receptor modulator and methods of treating diseases
|